EVAg

Infectious cell culture supernatant containing SARS-CoV-2 isolate SARS-CoV-2/human/ITA/INMI4/2020, clade GR, D614G (S). This strain is preserved under Viral Storage Medium -80C and is Mycoplasma free.

RNA of Human 2019-nCoV strain 2019-nCoV/Italy-INMI1. The RNA was obtained from a viral strain isolated in Italy, from a sample collected in January 29, 2020. To confirm its identity the virus has been completely sequenced. The complete sequence was submitted to GenBank (SARS-CoV-2/INMI1-Isolate/2020/Italy: MT066156) and is available on GISAID website (BetaCoV/Italy/INMI1-isl/2020: EPI_ISL_410545) upon registration. Import permit can be needed in your country. If yes, please indicate it in your online enquiry.

Infectious cell culture supernatant containing SARS-Cov-2 (strain human/DEU/HH-1/2020). This strain is preserved under Viral Storage Medium -80C. To confirm its identity the virus has been completely sequenced

Freeze-dried SARS-CoV-2 virus, strain UVE/SARS-CoV-2/2020/FR/702, France 2020, complete genome sequence.

Infectious cellculture supernatant of human 2019-nCoV

Infectious cell culture supernatant containing SARS-CoV-2 (strain hCoV-19/Netherlands/NoordBrabant_10003/2020, clade B, D614 (S)). This strain is preserved in viral storage medium -80°C.

Infectious cell culture supernatant containing SARS-CoV-2 (strain hCoV-19/Netherlands/ZuidHolland_10004/2020, D614G (S)). This strain is preserved in viral storage medium -80°C.

Infectious cell culture supernatant containing SARS-Cov-2 (strain Slovenia/SI-4265/20, D614G). This strain is preserved under Viral Storage Medium -80C. To confirm its identity the virus has been completely sequenced.

Infectious cell culture supernatant of human 2019-nCoV, clade G with D614G (S)

This SARS-CoV-2 strain was isolated from a COVID-19 patient from Slovakia in March 2020. Its complete sequence is deposited on GISAID.org under the accession ID EPI_ISL_417880.

Training in Coronavirus reverse genetics to adapt novel techniques (ISA method) to large RNA viruses and compare different technologies under BSL-3 conditions

Lyophilized encapsidated RNA for SARS-CoV-2 real time RT-PCR targeting region of the N(CUB) gene (for 100 Rxns) AND Lyophilized ready-to-use primers and probe (Lyoph-P&P) for real time RT-PCR (96 rxns in the form of 4x24 rnxs). Target, primers and probe designed by Charité (CUB) Berlin. SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase

Lyophilized ready-to-use primers and probe (Lyoph-P&P, 96 rxns in the form of 4x24 rxns) for real time RT-PCR of SARS-CoV-2 (2019-nCoV) in the N (CUB) gene. Primers and Probe sequences designed by Charité Universitätsmedizin Berlin; https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf). SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase For RUO (research use only)

Lyophilized encapsidated RNA for SARS-CoV-2 (2019-nCoV) real time RT-PCR targeting region of the N (CUB) gene, for 100 Rxns (Target designed by Charité Universitätsmedizin Berlin). The encapsidated RNA has been stabilized to serve as positive control for extraction and real time RT-PCR. Extraction is mandatory before use in real time RT-PCR. SOPs in the attached pdf. For RUO (Research Use Only)

This SARS-CoV-2 strain was isolated from a COVID-19 patient from Slovakia in March 2020. Its complete sequence is deposited on GISAID.org under the accession ID EPI_ISL_417879. The virus is freeze-dried.

This SARS-CoV-2 strain was isolated from a COVID-19 patient from Slovakia in march 2020. Its complete sequence is deposited on GISAID.org under the accesion ID EPI_ISL_417879.

Lyophilized encapsidated RNA for SARS-CoV-2 (2019-nCoV) real time RT-PCR targeting region of the RdRp (IP2/IP4) gene, for 100 Rxns (Target designed by Institut Pasteur: https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2) The encapsidated RNA has been stabilized to serve as positive control for extraction and real time RT-PCR. Extraction is mandatory before use in real time RT-PCR. SOPs in the attached pdf. For RUO (Research Use Only)

Lyophilized ready-to-use primers and probe (Lyoph-P&P, 96 rxns in the form of 4x24 rxns) for real time RT-PCR of SARS-CoV-2 (2019-nCoV) in the RdRp (IP4) gene. Primers and Probe sequences designed by Institut Pasteur: https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2) SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase For RUO (research use only)

Lyophilized encapsidated RNA for SARS-CoV-2 real time RT-PCR targeting region of the RdRp (IP2/IP4) gene (for 100 Rxns) AND Lyophilized ready-to-use primers and probe (Lyoph-P&P) for real time RT-PCR (96 rxns in the form of 4x24 rnxs). Target, primers and probe designed by Institut Pasteur Paris. SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase

Infectious cell culture supernatant containing Human 2019-nCoV strain 2019-nCoV/Italy-INMI1. This strain is preserved under Viral Storage Medium -80C. To confirm its identity the virus has been completely sequenced.

Infectious cell culture supernatant of human 2019-nCoV

The in vitro transcribed RNA is the control for the first-line screening assay termed E gene assay. The SARS-CoV full virus RNA is required to control the two confirmatory assays. Dislaimer: Import permit maybe be needed in your country for the SARS-CoV full virus RNA. If yes, please indicate so in your online enquiry.

In vitro transcribed RNA for Wuhan coronavirus (2019-nCoV) real time (RT-)PCR targeting region of the E gene . Protocol and preliminary evaluation for this assays (Corman/Drosten 2020), as of Jan 13, 2020, available from: https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2 Ref: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.3.2000045

Expression plasmid for the Nterminal Domain of the MERS CoV Nucleocapsid coding sequence in fusion with a TRX/6-His tag encoding sequence at its 5'. For expression in E. coli

Recombinant expressed and purified receptor-binding domain (RBD) of SARS-CoV-2 for serological assays. The Protein was expressed in Expi293 cells and purified via Strep-Tactin XT and provided in Elution Buffer ( 100mM Tris-HCl; pH 8.0, 150mM NaCl, 1mM EDTA, 50mM Biotin).